SNY vs. UHS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at SNY and UHS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
SNY trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, UHS is a standard domestic listing.
| Symbol | SNY | UHS |
|---|---|---|
| Company Name | Sanofi | Universal Health Services, Inc. |
| Country | France | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Providers & Services |
| Market Capitalization | 123.24 billion USD | 11.75 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | July 1, 2002 | July 9, 1981 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of SNY and UHS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | SNY | UHS |
|---|---|---|
| 5-Day Price Return | 3.98% | 3.33% |
| 13-Week Price Return | -7.74% | -6.16% |
| 26-Week Price Return | -16.60% | 1.03% |
| 52-Week Price Return | -13.80% | -18.82% |
| Month-to-Date Return | 9.70% | 10.96% |
| Year-to-Date Return | -7.73% | 2.94% |
| 10-Day Avg. Volume | 1.63M | 0.73M |
| 3-Month Avg. Volume | 2.04M | 0.89M |
| 3-Month Volatility | 24.79% | 31.65% |
| Beta | 0.72 | 1.30 |
Profitability
Return on Equity (TTM)
SNY
14.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
SNY’s Return on Equity of 14.92% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
UHS
18.62%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
In the upper quartile for the Health Care Providers & Services industry, UHS’s Return on Equity of 18.62% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
SNY
20.51%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 20.51% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
UHS
7.66%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
A Net Profit Margin of 7.66% places UHS in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
SNY
19.08%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
SNY’s Operating Profit Margin of 19.08% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
UHS
10.99%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
An Operating Profit Margin of 10.99% places UHS in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | SNY | UHS |
|---|---|---|
| Return on Equity (TTM) | 14.92% | 18.62% |
| Return on Assets (TTM) | 8.49% | 8.60% |
| Net Profit Margin (TTM) | 20.51% | 7.66% |
| Operating Profit Margin (TTM) | 19.08% | 10.99% |
| Gross Profit Margin (TTM) | 71.85% | -- |
Financial Strength
Current Ratio (MRQ)
SNY
1.27
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
SNY’s Current Ratio of 1.27 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
UHS
1.29
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
UHS’s Current Ratio of 1.29 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
SNY
0.32
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.32 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
UHS
0.65
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
UHS’s Debt-to-Equity Ratio of 0.65 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
UHS
9.05
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
UHS’s Interest Coverage Ratio of 9.05 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | SNY | UHS |
|---|---|---|
| Current Ratio (MRQ) | 1.27 | 1.29 |
| Quick Ratio (MRQ) | 0.94 | 1.19 |
| Debt-to-Equity Ratio (MRQ) | 0.32 | 0.65 |
| Interest Coverage Ratio (TTM) | 22.06 | 9.05 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
SNY
4.56%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.56%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
UHS
0.45%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
UHS’s Dividend Yield of 0.45% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
SNY
52.56%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
UHS
4.19%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
UHS’s Dividend Payout Ratio of 4.19% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | SNY | UHS |
|---|---|---|
| Dividend Yield (TTM) | 4.56% | 0.45% |
| Dividend Payout Ratio (TTM) | 52.56% | 4.19% |
Valuation
Price-to-Earnings Ratio (TTM)
SNY
9.57
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 9.57 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
UHS
9.33
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, UHS’s P/E Ratio of 9.33 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
SNY
1.96
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
SNY’s P/S Ratio of 1.96 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
UHS
0.71
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
UHS’s P/S Ratio of 0.71 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
SNY
1.44
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
SNY’s P/B Ratio of 1.44 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
UHS
1.66
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
UHS’s P/B Ratio of 1.66 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | SNY | UHS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 9.57 | 9.33 |
| Price-to-Sales Ratio (TTM) | 1.96 | 0.71 |
| Price-to-Book Ratio (MRQ) | 1.44 | 1.66 |
| Price-to-Free Cash Flow Ratio (TTM) | 10.47 | 13.05 |